SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life threatening pulmonary emboli, if administered ...

SUBLOCADE use during pregnancy showed no increased risk of birth defects, miscarriage, or maternal complications compared to general population rates RICHMOND, Va., May 1, 2025 /PRNewswire/ -- ...

Rapid initiation Protocol: Healthcare providers can now initiate treatment with SUBLOCADE after a single dose of transmucosal buprenorphine and a one-hour observation period to confirm tolerability. 1 ...

Total Net Revenue Expected in the Range of $1,125 million to $1,195 millionTotal SUBLOCADE- Net Revenue Expected to be in the Range of $905 million to $945 millionNon-GAAP Operating Expenses Expected ...

SLOUGH, England and RICHMOND, Va., April 16, 2020 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced the publication of long-term safety data for SUBLOCADE® (buprenorphine extended-release) ...

RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two ...

(RTTNews) - Indivior PLC (INDV, INDV.L), a specialty pharmaceutical company, announced Wednesday that the U.S. Food and Drug Administration has informed that the final review of the SUBLOCADE ...

SUBLOCADE Year-over-Year Growth: Expected to show 17% growth at the midpoint for fiscal year 2024. SUBLOCADE Net Revenue Forecast: Revised guidance due to increased competition and market dynamics.

Shares of Indivior (NASDAQ:INDV) dropped on Thursday after the dual-listed U.S. drugmaker lowered its fiscal 2024 guidance for the second time in roughly three months, citing sales headwinds related ...

If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as rapid induction one hour after a ...

Indivior PLC (NASDAQ:INDV) shares are trading lower after the company reported preliminary third-quarter revenue results and cut its FY24 net revenue guidance below estimates. The company expects ...

RICHMOND, Va. and SLOUGH, England, Nov. 30, 2017 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that the U.S. Food and Drug Administration (FDA) has approved SUBLOCADE TM (buprenorphine ...